Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (INMB) on April 24, 2024. The filing discloses the entry into a material definitive agreement regarding a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock and warrants.
- Shares Issued: 986,000 shares of common stock.
- Warrants Issued: Warrants to purchase 986,000 shares of common stock.
- Purchase Price: $9.84 per share and per warrant.
- Gross Proceeds: Approximately $9,702,240 (before deducting placement agent fees and expenses).
- Placement Agent Fee: 6.0% of gross proceeds paid to Maxim Group LLC.
- Warrant Terms: Exercise price of $9.84; termination date is the earlier of the two-year anniversary of the initial exercise date or 30 trading days following the reporting of positive top-line data (EMACC with a p-value ≤ 0.05) in the Phase 2 Alzheimer's program of XPro1595.
Note: This filing does not provide standard financial metrics such as revenue, net profit, operating cash flow, margins, or total debt, as it reports a specific capital raise event rather than periodic financial results.
Material Changes
The primary material change is the increase in the company's capital base through the sale of equity securities. The filing does not provide comparative financial data against prior periods to quantify changes in revenue or profitability.
Outlook, Risks, and Management Commentary
- Closing Date: The offering is expected to close on or about April 29, 2024, subject to customary closing conditions.
- Use of Proceeds: The filing text does not explicitly state the intended use of proceeds, though the warrant termination clause is tied to clinical trial milestones for the XPro1595 Alzheimer's program.
- Risks/Contingencies: The transaction is contingent on the satisfaction of customary closing conditions. The warrant structure introduces a specific contingency related to clinical trial data reporting.
Key Facts for Investor Verification
- Verify the final closing date and net proceeds after the deduction of the 6% placement agent fee and other transaction expenses.
- Confirm the exact number of shares outstanding post-offering to assess dilution impact.
- Monitor the Phase 2 Alzheimer's program for XPro1595, as positive top-line data will trigger the early termination of the warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Placement Agency Agreement (Exhibit 10.2) for additional covenants or restrictions.